Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Second COVID-19 Vaccine Booster Dose Update

Last updated on

On March 29, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccines as follows:

  • Authorization for individuals 50 years or older of a second booster dose, if at least 4 months after the first booster dose, of any authorized or approved COVID-19 vaccine.
  • Authorization for immunocompromised individuals of a second booster dose, if at least 4 months after the first booster dose, of any authorized or approved COVID-19 vaccine, subject to the following age-specific limitations for particular vaccines:
    • The Pfizer-BioNTech COVID-19 vaccine is indicated for individuals 12 years or older.
    • The Moderna COVID-19 vaccine is indicated for individuals 18 years or older.

The Texas Health and Human Services Commission allows for pharmacy benefit coverage of the Pfizer-BioNTech and Moderna COVID-19 vaccines in compliance with the expanded use authorized by the FDA.

Details are available on the Texas Medicaid & Healthcare Partnership (TMHP) website at www.tmhp.com.

Contact vdp-formulary@hhsc.state.tx.us with any comments or questions.